Kinnate Receives Fast Track Designation for KIN-2787
Kinnate Biopharma has received Fast Track designation from the FDA for KIN-2787, an investigational treatment for certain patients with malignant melanoma that is metastatic or unresectable.
The designation is specifically for treatment of patients with stage IIb to IV and BRAF Class II or III alteration-positive and/or NRAS mutation-positive melanomas.
KIN-2787 inhibits certain enzymes that play an important role in cellular growth, to block the formation of growths that may become cancer.
The drug is being evaluated in a phase 1 clinical trial in patients with solid tumors harboring BRAF alterations or who have NRAS mutant melanoma.
The FDA previously granted the investigational drug an Orphan Drug designation for treatment of stage IIb-IV melanoma.